AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02620995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
Study NCT01687296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate inhalation solution
Description: 2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
Study NCT01687296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral prednisone
Description: once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
Study NCT01687296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo inhalation solution
Description: 4ml 0.9% saline nebulized twice daily
Study NCT01687296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo tablet
Description: placebo soluble tablet, oral ,once daily
Study NCT01687296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
Study NCT01687296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
Study NCT01865227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Counseling
Study NCT04041934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tryptophan
Description: Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
Study NCT01201720 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plasma exchange with albumin
Description: Realization of 6 plasma exchange with albumin in 11 days
Study NCT00673582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg/day rosuvastatin
Study NCT00673582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 10 mg a day for 96 weeks
Study NCT02018081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 8 blood sampling by patients between the 48th and 60th
Study NCT02478463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir tablet 30 mg once daily for 28 days.
Description: GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
Study NCT02478463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.
Description: Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL \[600 mg\] total) IM given once on Day 1 of injection phase
Study NCT02620995 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: comparator group
Description: Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
Study NCT04848155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: socially assistive robot
Description: The intervention group will work with the ReMIND-system. This ReMIND-system consists of:~1. An existing socially assistive robot called James® that will be adapted based on the needs of the older adults and the robot's own functionality. For example, exercise videos and games to stimulate physical and cognitive activity will be developed and made available on the robot. The robot has to be programmed by the researcher using the ZBOS Control© application on a separate tablet that is connected to the robot.~2. The Keosity-app, an application specifically designed to support people in telling, documenting and sharing their life stories with others. This application will be available on the robot.
Study NCT01458535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets
Study NCT00993538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Study NCT00993538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Study NCT05206760 — intervention group
Intervention type: PROCEDURE
Intervention: Brain biopsy
Description: Biopsy of brain tissue
Study NCT04577378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole
Description: After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
Study NCT04577378 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)
Description: Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
Study NCT01054456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonesetron
Description: One dose administered intravenously 30 minutes pre-chemotherapy
Study NCT01688375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
Study NCT01458535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: capsules
Study NCT00756431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Fracture reduction Screw without HA Coating (Hiploc)
Description: Hip Fracture reduction Screw without HA Coating (Hiploc)
Study NCT00756431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip Fracture reduction Screw with HA Coating (Hiploc)
Description: Hip Fracture reduction Screw with HA Coating (Hiploc)
Study NCT02558855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thrust Joint Manipulation of the Lumbar Spine
Study NCT02558855 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-thrust Joint Manipulation of the Lumbar Spine
Study NCT02509923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 10mg
Description: Z-215 10mg, capsules
Study NCT02509923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 20mg
Description: Z-215 20mg, capsules
Study NCT02509923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 10mg
Description: Rabeprazole Sodium 10mg tablets
Study NCT02509923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 20mg
Description: Rabeprazole Sodium 20mg tablets
Study NCT03918421 — intervention group
Intervention type: OTHER
Intervention: Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)
Description: Rasch-built overall Disability Scale (RODS) is a disease-specific, patient-based, linearly weighted scale that captures activity and social participation limitations to detect activity limitations in patients with Immunogloblin M (IgM) anti-myelin-associated-glycoprotein peripheral neuropathy. For this study, the preliminary RODS is a 146 item patient-reported outcome instrument that assesses activity and social participation limitation. Rasch Measurement Methods examine the extent observed data (patients' actual responses to scale items) accord with predictions of those responses from a mathematical model.
Study NCT01292187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral calcitonin at dinnertime
Description: Oral calcitonin at dinnertime.
Study NCT01292187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo at dinnertime
Description: Oral placebo at dinnertime.
Study NCT01292187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral calcitonin at bedtime
Description: Oral calcitonin at bedtime
Study NCT01292187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo at bedtime
Description: Oral placebo at bedtime
Study NCT00059345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Electroacupuncture treatments provided two times per week for 6 weeks
Study NCT00059345 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture treatments provided 2 times per week for 6 weeks
Study NCT00059345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care for knee osteoarthritis
Study NCT01584310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire STAMP and dietary
Description: Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
Study NCT01584310 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No STAMP using
Description: No intervention
Study NCT03655041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: Beta-alanine in sustained-release tablets to increase muscle carnosine content
Study NCT03655041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine
Study NCT03400826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
Study NCT03400826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 40 mg
Description: The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
Study NCT01669486 — intervention group
Intervention type: OTHER
Intervention: CPOT, BPS
Description: Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
Study NCT02691559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic fluid analysis by blood gas device
Description: Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
Study NCT02414685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
Study NCT02414685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
Study NCT03667781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Therapeutic drug monitoring
Description: Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
Study NCT02414685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
Study NCT02396212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.
Study NCT02346175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Study NCT02346175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02470520 — intervention group
Intervention type: PROCEDURE
Intervention: CRRT
Description: continuous renal replacement therapy
Study NCT02883803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of mesenchymal stem cells
Description: Injection of mesenchymal stem cells
Study NCT02883803 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Injection of albumin alone
Description: Injection of albumin alone
Study NCT02133898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: L-methylfolate
Description: L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
Study NCT03703544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycemic index
Description: Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
Study NCT03703544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index
Description: Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
Study NCT01561235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose-reponse effect of protein on appetite and appetite-regulating hormones
Description: 3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
Study NCT01561235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dose-reponse effect of protein on appetite and appetite-regulating hormones
Description: 3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
Study NCT04579341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: probiotics administration
Study NCT03869554 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of Fabry disease
Description: Systematic detection of Fabry disease
Study NCT00679835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
Study NCT01721863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
Study NCT02591940 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery or Treatment by Heart Catheter
Study NCT04508426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AR882
Description: Single dose of \[14C\]AR882
Study NCT01362348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: 10 mg/mL (1 drop) four times daily
Study NCT01534000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac computed tomographic angiography (CCTA)
Description: Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
Study NCT05254106 — intervention group
Intervention type: DEVICE
Intervention: Lower limb artery revascularization with paclitaxel-eluting device
Description: Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon
Study NCT02535143 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test Cavity Preparation
Description: Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
Study NCT02535143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Cavity Preparation
Description: Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
Study NCT02535143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine
Description: 250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
Study NCT02535143 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post intervention test cavity
Description: Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
Study NCT02535143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post intervention test cavity
Description: Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
Study NCT02535143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbonated Apple Juice
Description: 250ml of commercially available carbonated apple juice to be administered three hours after the last meal and half an hour prior to performing the second test cavity
Study NCT03349658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: effect of general anesthesia on transcranial regional cerebral oxygen saturation
Study NCT03349658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: effect of spinal anesthesia on transcranial regional cerebral oxygen saturation
Study NCT03062514 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PINS Vagus Nerve Stimualtor
Description: PINS Vagus Nerve Stimualtor
Study NCT03062514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINS Vagus Nerve Stimualtor
Description: PINS Vagus Nerve Stimualtor
Study NCT03196544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Approach Training (5 sessions)
Description: 5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
Study NCT03196544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Approach Training (10 sessions)
Description: 10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
Study NCT04314986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days
Study NCT04314986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 1: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days
Study NCT01135147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Dietary therapy and physical education
Study NCT01135147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Adenotonsillectomy along with diet and physical therapy
Study NCT04314986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days.
Study NCT04314986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 2: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days.
Study NCT04314986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days
Study NCT04314986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 3: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days